ORCID as entered in ROS

Select Publications
2020, 'Combined utility of blood glucose and white blood cell in predicting outcome after acute ischemic stroke: The ENCHANTED trial', Clinical Neurology and Neurosurgery, 198, http://dx.doi.org/10.1016/j.clineuro.2020.106254
,2020, 'Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm', Cerebrovascular Diseases, 49, pp. 427 - 436, http://dx.doi.org/10.1159/000509226
,2020, 'Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome: Pooled Analysis of 20 000+ Patients', Stroke, 51, pp. 2411 - 2417, http://dx.doi.org/10.1161/STROKEAHA.119.028523
,2020, 'Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial', Stroke, 51, pp. 588 - 593, http://dx.doi.org/10.1161/STROKEAHA.119.027639
,2020, 'Thrombolysis Outcomes in Acute Ischemic Stroke by Fluid-Attenuated Inversion Recovery Hyperintense Arteries', Stroke, 51, pp. 2240 - 2243, http://dx.doi.org/10.1161/STROKEAHA.119.028550
,2020, 'Abstract TMP15: Asian versus Non-Asian, Differences in Characteristics, Management & Outcomes in the Enchanted Trial', Stroke, 51, http://dx.doi.org/10.1161/str.51.suppl_1.tmp15
,2019, 'Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial', Lancet, 393, pp. 877 - 888, http://dx.doi.org/10.1016/S0140-6736(19)30038-8
,2019, 'Abstract TP362: Comparison of the Simplified Modified Rankin Scale Questionnaire With Conventional Neurological Scales in the Dose Arm of the Enchanted Study', Stroke, 50, http://dx.doi.org/10.1161/str.50.suppl_1.tp362
,2018, 'Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.', International Journal of Stroke, pp. 1 - 4, http://dx.doi.org/10.1177/1747493018806170
,2017, 'Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial', Stroke and Vascular Neurology, 2, pp. 53 - 58, http://dx.doi.org/10.1136/svn-2017-000085
,2017, 'Intracerebral hemorrhage location and outcome among INTERACT2 participants', Neurology, 88, pp. 1408 - 1414, http://dx.doi.org/10.1212/WNL.0000000000003771
,2017, 'Associations with health-related quality of life after intracerebral haemorrhage: Pooled analysis of INTERACT studies', Journal of Neurology Neurosurgery and Psychiatry, 88, pp. 70 - 75, http://dx.doi.org/10.1136/jnnp-2016-314414
,2016, 'Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke', New England Journal of Medicine, 374, pp. 2313 - 2323, http://dx.doi.org/10.1056/NEJMoa1515510
,2016, 'White blood cell count and clinical outcomes after intracerebral hemorrhage: The INTERACT2 trial', Journal of the Neurological Sciences, 361, pp. 112 - 116, http://dx.doi.org/10.1016/j.jns.2015.12.033
,2015, 'Statistical analysis plan for evaluating low- vs. Standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)', International Journal of Stroke, 10, pp. 1313 - 1315, http://dx.doi.org/10.1111/ijs.12602
,2015, 'Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2×2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment', International Journal of Stroke, 10, pp. 778 - 788, http://dx.doi.org/10.1111/ijs.12486
,2014, 'Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INTERACT2', Stroke, 45, pp. 258 - 260, http://dx.doi.org/10.1161/Strokeaha.113.003524
,